Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Embrace

- PMLiVE

Sanofi/Regeneron’s Kevzara approved by FDA for polyarticular juvenile idiopathic arthritis

The chronic disease is designated as one of the three major types of juvenile idiopathic arthritis

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

- PMLiVE

Sanofi and Regeneron share positive late-stage results for Dupixent in COPD

About 300,000 people in the US have uncontrolled COPD and evidence of type 2 inflammation

- PMLiVE

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

- PMLiVE

Sanofi gains rights to Fulcrum’s muscular dystrophy treatment in deal worth more than $1bn

Losmapimod is being investigated as a potential transformative therapy for the rare disease

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links